ABLYNX ANNOUNCES A THIRD EXTENSION OF ITS ANTI-TNF-ALPHA NANOBODY COLLABORATION WITH PFIZER
(Thomson Reuters ONE) -
GHENT, Belgium, 20 May 2010 - Ablynx [Euronext Brussels: ABLX] announced today
that the research collaboration which forms part of its license agreement for
Nanobodies to tumour necrosis factor alpha (TNF-alpha) with Pfizer has been
extended for another year.
Ablynx announced the exclusive research collaboration and license agreement with
Pfizer (originally signed with Wyeth Pharmaceuticals) in November 2006, a deal
potentially worth $212.5 million in past and future milestone payments for
commercialisation across multiple indications. In addition, Ablynx is eligible
to receive royalties on product sales. Under this agreement, Pfizer has
exclusive rights to develop and commercialise anti-TNF-alpha Nanobodies
developed under the collaboration. The lead Nanobody-based candidate is in a
Phase II study in patients with rheumatoid arthritis.
The license agreement includes a research collaboration where Pfizer and Ablynx
are working together to discover and develop additional Nanobody-based
therapeutics against TNF-alpha. TNF-alpha is a key drug target in combating
inflammation related disorders such as rheumatoid arthritis, Crohn's disease,
psoriatic arthritis and ankylosing spondylitis.
Dr. Edwin Moses, CEO and Chairman of Ablynx, commented:
"We are delighted with this research collaboration extension and the rapid
progress made in the partnership with Pfizer. We look forward to seeing the lead
Nanobody candidate progress through Phase II trials, as well as working towards
the goal of advancing additional anti-TNF-alpha ?Nanobodies towards the clinic.
There are now four Nanobodies( )in clinical trials including Ablynx's two
anti-thrombosis programmes and an anti-RANKL programme."
-ends-
About Ablynx [Euronext Brussels: ABLX] - http://www.ablynx.com
Founded in 2001 in Ghent, Belgium, Ablynx is a biopharmaceutical company focused
on the discovery and development of Nanobodies, a novel class of therapeutic
proteins based on single-domain antibody fragments, for a range of serious and
life-threatening human diseases. The Company currently has over 230 employees.
Ablynx completed a successful IPO on Euronext Brussels [ABLX] on 7 November
2007 and raised ?50 million through an SPO in March 2010.
For more information, please contact Ablynx:
Dr. Edwin Moses
Chairman and CEO
t: +32 (0)9 262 00 07
m: +44 (0)7771 954 193 / +32 (0)473 39 50 68
e: edwin.moses(at)ablynx.com
Eva-Lotta Allan
Chief Business Officer
t: +32 (0)9 262 00 75
m: +32 (0)475 78 36 21 / +44 (0)7990 570 900
e: eva-lotta.allan(at)ablynx.com
[HUG#1417768]
Complete version of the press release: http://hugin.info/137912/R/1417768/368175.pdf
Unternehmensinformation / Kurzprofil:
Datum: 20.05.2010 - 18:02 Uhr
Sprache: Deutsch
News-ID 21265
Anzahl Zeichen: 0
contact information:
Town:
Ghent
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 201 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"ABLYNX ANNOUNCES A THIRD EXTENSION OF ITS ANTI-TNF-ALPHA NANOBODY COLLABORATION WITH PFIZER"
steht unter der journalistisch-redaktionellen Verantwortung von
Ablynx (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
